Abstract
Urinary excretion of thromboxane B 2 (TXB 2), a stable metabolite of thromboxane A 2 (TXA 2), was measured by radioimmunoassay in 7 essential hypertensive patients before and after a converting enzyme inhibitor, SQ 14225, administration. When a single oral dose of SQ 14225 (50mg) was given to 7 patients with essential hypertension, urinary excretion of TXB 2 was increased significantly ( from 58.9 ± 18.1 to 116.1 ± 20.7 pg/min, mean ± SE, P < 0.02 ) with simultaneous increase in plasma renin activity, urine volume, urinary sodium, urinary potassium and urinary excretion of PGE (from 58.8 ± 12.8 to 135.1 ± 30.0 pg/min, mean ± SE, P < 0.05 ). These results indicate that SQ 14225 stimulates vasoconstricting TXA 2 production as well as vasodilating PGE production.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
